| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 4030.6 | 3442.9 | 3570.3 |
| Other income | 45.0 | 114.3 | 79.9 |
| Total income | 4075.6 | 3557.2 | 3650.2 |
| Profit before exceptional items & tax | 769.5 | 682.3 | 540.5 |
| Exceptional items | 0.0 | 23.2 | 0.0 |
| Profit before tax | 769.5 | 659.2 | 540.5 |
| Net profit | 574.1 | 559.4 | 444.6 |
| Operating margin | 18.9% | 18.5% | 14.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +29.10% |
|---|---|
| Net profit, quarter on quarter | +2.60% |
| Revenue, year on year | +12.90% |
| Operating profit, year on year | +45.10% |
| Operating profit, quarter on quarter | +18.90% |
BSE results filing, NSE: MANKIND. Figures extracted from the filing.
Mankind Pharma Ltd: key numbers
- Share price
- ₹2,474.90
- Market cap
- ₹1,02,225 Cr
- Revenue (annual)
- ₹14,278 Cr
- Net profit (annual)
- ₹1,913 Cr
- P/E (TTM)
- 50.0×Sector 50.4×
- Promoter holding
- 72.63%-0.03% QoQ
- FII holding
- 9.45%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mankind Pharma Ltd
All →Mankind Pharma Annual General Meeting
Mankind Pharma announced the successful passing of a special resolution to appoint Mr. Anish Vanraj Bafna as a Non-Executive Independent Director. The Postal Ballot concluded with the required majority.
Mankind Pharma Other Announcement
Mankind Pharma has been assigned an ESG rating of 68.21 ('Leader' category) by Niche99 ESG Ratings, based on publicly available data for FY 2025-26.
Mankind Pharma Merger & Restructuring
Mankind Pharma announced that members of its wholly-owned subsidiary, Bharat Serums and Vaccines Limited (BSVL), approved its voluntary liquidation in an EGM.
Mankind Pharma Earnings Call Transcript: Key Takeaways
Mankind Pharma's FY25 ESG report highlights a 73% carbon reduction since FY21 and 63% renewable energy mix. The company is focused on embedding sustainable practices across manufacturing and its value chain.
Mankind Pharma Investor Presentation: Key Takeaways
Mankind Pharma reported strong Q1 FY27 results with 12.9% revenue growth and 29.1% PAT growth. Strategy focuses on chronic segment expansion, BSV integration, and OTC growth.
Mankind Pharma Earnings Call: Key Takeaways
Mankind Pharma reported strong Q4 FY26 results with 11.8% revenue growth and 27.1% EBITDA margins, driven by chronic therapy outperformance and steady recovery in acute segments.